AbbVie Inc (ABBV)vsLigand Pharmaceuticals Incorporated (LGND)
ABBV
AbbVie Inc
$227.23
-2.14%
HEALTHCARE · Cap: $391.50B
LGND
Ligand Pharmaceuticals Incorporated
$237.00
+0.46%
HEALTHCARE · Cap: $5.12B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 22787% more annual revenue ($62.82B vs $274.48M). LGND leads profitability with a 55.9% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.61. LGND earns a higher WallStSmart Score of 67/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
LGND
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$227.23
$81.01 premium
Margin of Safety
-15.9%
Fair Value
$160.49
Current Price
$237.00
$76.51 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Keeps 56 of every $100 in revenue as profit
Strong operational efficiency at 33.6%
Earnings expanding 103.2% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : LGND
The strongest argument for LGND centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 55.9% and operating margin at 33.6%. Revenue growth of 14.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : LGND
The primary concerns for LGND are PEG Ratio, P/E Ratio.
Key Dynamics to Monitor
ABBV profiles as a value stock while LGND is a mature play — different risk/reward profiles.
LGND carries more volatility with a beta of 1.04 — expect wider price swings.
LGND is growing revenue faster at 14.1% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
LGND scores higher overall (67/100 vs 63/100), backed by strong 55.9% margins and 14.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ligand Pharmaceuticals Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?